Key result
Pilsicainide significantly decreased the number of wavefronts per frame from 1.61 to 1.00 and prolonged the atrial effective refractory period in a canine model of atrial fibrillation.
Why the study?
Does pilsicainide alter atrial fibrillation wavefront dynamics and electrophysiological parameters in a canine model?
Does pilsicainide alter atrial fibrillation wavefront dynamics and electrophysiological parameters in a canine model?
Absolute Event Rate: 1% vs 1.61%
p-value: p=<0.05
In a canine model, pilsicainide terminates atrial fibrillation by prolonging the atrial effective refractory period and wavelength, leading to an enlargement of excitation circuits and a reduction in the number of wavefronts.
No takes yet. Share an insight, caveat, or question.
Kanki et al. (1999) studied Atrial fibrillation (n=4). Pilsicainide vs. Baseline (pre-drug) was evaluated on Number of wavefronts per frame (p=<0.05). Pilsicainide significantly decreased the number of wavefronts per frame from 1.61 to 1.00 and prolonged the atrial effective refractory period in a canine model of atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: